---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-111207"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2026-10-21T13:00:34+00:00"
generated_at: "2026-10-21T13:02:09.695032+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INmune Bio submits Ebstrocel pre-MAA to UK MHRA, targets approval in mid-2027

## Summary
- Submitted final pre-MAA package for Ebstrocel (CORDStrom) to the UK MHRA on October 20, 2026; full MAA targeted for early February 2027.
- INmune Bio says the revised strategy could accelerate potential UK approval by about six weeks, with possible approval in mid-2027 subject to MHRA review.
- Signed a Master Services Agreement with Uniphar Durbin Ireland to support named-patient access in selected European and MENA markets.
- Plans a Type B meeting request with the FDA and a BLA submission in Q2 2027, seeking traditional or accelerated approval as appropriate.

## SEC filing metadata
- accession: 0001213900-26-111207
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2026-10-21T13:00:34+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/0001213900-26-111207-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390026111207/ea0309223-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-111207
- JSON: https://secwatch.observer/filing/0001213900-26-111207.json
- Plain text: https://secwatch.observer/filing/0001213900-26-111207.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.